Alterity Therapeutics CEO to Present at Bell Potter Healthcare Conference
ATH: $0.250 -9.09% · MC: $57M
Alterity Therapeutics CEO David Stamler will present at the virtual Bell Potter Healthcare Conference on 19 November, with an archived webcast to be made available on the company’s website. Alterity is preparing a pivotal Phase 3 trial of ATH434 for multiple system atrophy, following confirmation of the trial design and regulatory pathway in its recent quarterly update.

Comments